EDITORIAL

REVIEW

MINIREVIEWS


ORIGINAL ARTICLE
Case Control Study

Retrospective Cohort Study


Retrospective Study

Observational Study
Contents

Quarterly Volume 14 Number 3 September 20, 2024

Hunjah BA, Hamza H, Qasba RK, Nawaz FA, Surani S, Kashyap R. Violence study of healthcare workers and
i3.92932]

Randomized Clinical Trial

Jain M, Khan S, Varghese P, Tripathy SK, Mangaraj M. Botulinum toxin type A for treating chronic low back
93854]

SYSTEMATIC REVIEWS


META-ANALYSIS

Iqbal K, Banga A, Arif TB, Rathore SS, Bhurwal A, Naqvi SKB, Mehdi M, Kumar P, Salklan MM, Iqbal A,
prevent COVID-19 associated acute venous thromboembolism or not: A systematic review and meta-analysis.

LETTER TO THE EDITOR

Silva HM. Reckoning with COVID-19 denial: Brazil's exemplary model for global response. World J Methodol 2024;
ABOUT COVER
Peer Reviewer of World Journal of Methodology, Mohammad Sultan Khuroo, MD, DM, FRCP (Edin), FACP, Master American College of Physicians (MACP, Emeritus), Digestive Diseases Centre, Dr. Khuroo’s Medical Clinic, Srinagar. khuroo@yahoo.com.

AIMS AND SCOPE
The primary aim of World Journal of Methodology (WJM, World J Methodol) is to provide scholars and readers from various fields of methodology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJM mainly publishes articles reporting research results obtained in the field of methodology and covering a wide range of topics including breath tests, cardiac imaging techniques, clinical laboratory techniques, diagnostic self-evaluation, cardiovascular diagnostic techniques, digestive system diagnostic techniques, endocrine diagnostic techniques, neurological diagnostic techniques, obstetrical and gynecological diagnostic techniques, ophthalmological diagnostic techniques, otological diagnostic techniques, radioisotope diagnostic techniques, respiratory system diagnostic techniques, surgical diagnostic techniques, etc.

INDEXING/ABSTRACTING
The WJM is now abstracted and indexed in PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Lei Zhang; Production Department Director: Xu Gan; Cover Editor: Ji-Hong Liu.

NAME OF JOURNAL
World Journal of Methodology

ISSN
ISSN 2222-0682 (online)

LAUNCH DATE
September 26, 2011

FREQUENCY
Quarterly

EDITORS-IN-CHIEF
Timotius Ivan Hariyanto

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2222-0682/editorialboard.htm

PUBLICATION DATE
September 20, 2024

COPYRIGHT
© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: office@baishideng.com https://www.wjgnet.com
Semaglutide for the management of diabesity: The real-world experience

Mohammed Alkhalifah, Hafsa Afsar, Anindya Shams, Dania Blaibel, Vishnu Chandrabalan, Joseph M Pappachan

Specialty type: Endocrinology and metabolism
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Wang Z, China
Received: January 6, 2024
Peer-review started: January 6, 2024
First decision: January 28, 2024
Revised: January 29, 2024
Accepted: March 1, 2024
Article in press: March 1, 2024
Published online: September 20, 2024
Processing time: 170 Days and 18.7 Hours

Mohammed Alkhalifah, Hafsa Afsar, Anindya Shams, Dania Blaibel, Joseph M Pappachan, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom

Mohammed Alkhalifah, Department of Family Medicine, King Faisal Specialist Hospital, Riyadh 11211, Saudi Arabia

Vishnu Chandrabalan, Department of Data Science, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom

Joseph M Pappachan, Faculty of Science, Manchester Metropolitan University, Manchester M15 6BH, United Kingdom

Joseph M Pappachan, Faculty of Biology, Medicine & Health, The University of Manchester, Manchester M13 9PL, United Kingdom

Corresponding author: Joseph M Pappachan, MD, FRCP, Academic Editor, Consultant Endocrinologist, Professor, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane, Preston PR2 9HT, United Kingdom.
drpappachan@yahoo.co.in

Abstract

BACKGROUND
Diabesity (diabetes as a consequence of obesity) has emerged as a huge healthcare challenge across the globe due to the obesity pandemic. Judicious use of anti-diabetic medications including semaglutide is important for optimal management of diabesity as proven by multiple randomized controlled trials. However, more real-world data is needed to further improve the clinical practice.

AIM
To study the real-world benefits and side effects of using semaglutide to manage patients with diabesity.

METHODS
We evaluated the efficacy and safety of semaglutide use in managing patients with diabesity in a large academic hospital in the United States. Several parameters were analyzed including demographic information, the data on impro-
vement of glycated hemoglobin (HbA1c), body weight reduction and insulin dose adjustments at 6 and 12 months, as well as at the latest follow up period. The data was obtained from the electronic patient records between January 2019 to May 2023.

**RESULTS**

106 patients (56 males) with type 2 diabetes mellitus (T2DM), mean age 60.8 ± 11.2 years, mean durations of T2DM 12.4 ± 7.2 years and mean semaglutide treatment for 2.6 ± 1.1 years were included. Semaglutide treatment was associated with significant improvement in diabesity outcomes such as mean weight reductions from baseline 110.4 ± 24.6 kg to 99.9 ± 24.9 kg at 12 months and 96.8 ± 22.9 kg at latest follow up and HbA1c improvement from baseline of 82 ± 21 mmol/mol to 67 ± 20 at 12 months and 71 ± 23 mmol/mol at the latest follow up. An insulin dose reduction from mean baseline of 95 ± 74 units to 76.5 ± 56.2 units was also observed at the latest follow up. Side effects were mild and mainly gastrointestinal like bloating and nausea improving with prolonged use of semaglutide.

**CONCLUSION**

Semaglutide treatment is associated with significant improvement in diabesity outcomes such as reduction in body weight, HbA1c and insulin doses without major adverse effects. Reviews of largescale real-world data are expected to inform better clinical practice decision making to improve the care of patients with diabesity.

**Key Words:** Type 2 diabetes mellitus; Diabesity; Glucagon-like peptide 1 receptor agonists; Semaglutide; Insulin dose reduction; Weight loss

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
of semaglutide (1 mg) subcutaneously weekly for the management of T2DM, while Semaglutide Treatment Effect in People with Obesity (STEP) Trial tested the efficacy of the molecule (at 2.4 mg weekly dose) for body weight management [4]. These large multinational randomized controlled clinical trials (RCTs), viz., SUSTAIN 1-11, PIONEER 1-12 and STEP 1-6 trials, demonstrated the efficacy and safety of semaglutide as an antidiabetic medication with good weight loss potential beyond doubt.

As the settings of RCTs and prospective observational studies are well-supervised and often rigorously scrutinized by research teams, the study results captured by these methods may not always reflect the actual real-world clinical picture in our day-to-day medical practice. Therefore, it is imperative to have real-world clinical data for truly appraising the actual immediate and long-term efficacy and safety of semaglutide to aid therapeutic decision making for patients with diabesity and T2DM. The present study is such an attempt to gather the real-world data from patients managed on long-term basis with semaglutide for diabesity in a large academic teaching hospital in the UK.

MATERIALS AND METHODS

Study design and settings
This is a retrospective clinical study by review of the clinical and therapeutic data of all patients managed with any one of the injectable (brand: Ozempic), or oral (brand: Rybelsus) semaglutide agents, between January 1, 2019 and May 31, 2023 at Lancashire Teaching Hospitals NHS Trust (LTHTR). The endocrine and metabolic service of this hospital provides comprehensive diabetic care for patients in the Central Lancashire and South Cumbria regions of the UK, with a population of about 0.4 million people. The study was approved by the institutional audit/research committee (No: DIAB/CA/2022-23-08).

Participants
All adult patients (aged ≥ 18 years) with T2DM treated by one of the above GLP-1RA molecules for management of their diabetes were considered for inclusion in the study.

Data capture
Electronic medical records were searched for all patients with a diagnosis of diabetes mellitus treated with semaglutide during the study period. The total number of cases in this category were further reviewed for inclusion in the study.

Inclusion criteria
(1) Patients with a diagnosis of T2DM managed with injectable or oral semaglutide; and (2) Participants with predefined primary outcome measures (HbA1c alteration from baseline values to different follow-up periods) and/or secondary outcomes such as alterations in body weight, as well as reduction in insulin dose – all these outcomes with meaningful data in at least one of the follow-up periods (6 months, 12 months and/or at the last follow up just prior to completion of the study). Additional factors examined were blood pressure, renal functions, and urine albumin creatinine ratio.

Exclusion criteria
(1) Patients with a diagnosis of type 1 diabetes mellitus; (2) Incomplete study data to obtain meaningful outcome measures as specified above; and (3) Follow-up duration less than 6 months.

Data collection
Data was collected by reviewing each case fulfilling the inclusion criteria identified from the total number of cases in the electronic patient record system (Flex) of the LTHTR. Microsoft Excel spreadsheet was used for data compilation and rechecked for logical inconsistency and entry error. Data was cleaned accordingly before analysis.

Data analysis
Data management and statistical analysis were done using statistical package for social sciences (SPSS software Version 26). The analysis included frequency distribution, cross-tabulation as well as descriptive statistical analysis. Paired t-test was performed to ascertain statistical significance of change in glycemic status, weight, and dose of insulin before and after semaglutide therapy. The results were presented in tables and graphs.

RESULTS
A total of 106 patients with T2DM on semaglutide were included in this study. 56 were males and the remainder females. Table 1 shows their baseline clinical and biochemical characteristics. The data analysis has been done separately for male and female patients for each of the variables. The mean (SD) duration of diabetes was 12.4 (7.2) years, and the mean follow up duration after initiation of semaglutide was 2.6 (1.1) years, and the Table 2 shows other different anti-diabetic medications received by patients prior to the initiation of semaglutide. Among different anti-diabetic drugs, 69.8% patients were on metformin, 69.8% were on insulin and 51.9% were on sodium glucose cotransporter 2 (SGLT2) inhibitors.
Table 1 Baseline characteristics of 106 type 2 diabetes mellitus patients treated with semaglutide

<table>
<thead>
<tr>
<th>Attributes</th>
<th>Male</th>
<th>Female</th>
<th>All</th>
<th>Reference value (if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td></td>
</tr>
<tr>
<td>Patient age (years)</td>
<td>60.88 (10.04)</td>
<td>60.64 (12.43)</td>
<td>60.76 (11.18)</td>
<td></td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>140.43 (18.42)</td>
<td>136.79 (15.18)</td>
<td>138.86 (17.02)</td>
<td></td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
<td>80.32 (10.82)</td>
<td>71.32 (10.62)</td>
<td>76.45 (11.56)</td>
<td></td>
</tr>
<tr>
<td>Patient baseline weight (kg)</td>
<td>111.45 (21.07)</td>
<td>109.05 (28.63)</td>
<td>110.36 (24.56)</td>
<td></td>
</tr>
<tr>
<td>Patient baseline HbA1c (mmol/mol)</td>
<td>84.18 (22.20)</td>
<td>79.46 (19.40)</td>
<td>81.96 (20.96)</td>
<td>20-41 mmol/mol</td>
</tr>
<tr>
<td>Serum creatinine (μmol/L)</td>
<td>101.16 (53.98)</td>
<td>75.33 (37.18)</td>
<td>89.34 (48.52)</td>
<td>Male: 59-104 μmol/L; Female: 45-84 μmol/L</td>
</tr>
<tr>
<td>Urine ACR (mg/mmol)</td>
<td>21.96 (38.26)</td>
<td>28.74 (58.59)</td>
<td>24.97 (47.81)</td>
<td>Male: &lt; 2.5 mg/mmol; Female: &lt; 3.5 mg/mmol</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>4.10 (1.47)</td>
<td>4.53 (1.61)</td>
<td>4.29 (1.35)</td>
<td>&lt; 5.01 mmol/L</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>1.07 (0.34)</td>
<td>1.16 (0.36)</td>
<td>1.11 (0.35)</td>
<td>&gt; 1 mmol/L</td>
</tr>
<tr>
<td>Triglyceride (mmol/L)</td>
<td>4.82 (5.79)</td>
<td>5.02 (2.62)</td>
<td>4.89 (4.60)</td>
<td>&lt; 2.3 mmol/L</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>25.50 (15.04)</td>
<td>23.73 (11.17)</td>
<td>24.69 (13.33)</td>
<td>0-33 U/L</td>
</tr>
</tbody>
</table>

ALT: Alanine transaminase; ACR: Albumin creatinine ratio; HbA1c: Glycated hemoglobin; HDL: High-density lipoprotein.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Total patients</th>
<th>Percentage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin</td>
<td>74</td>
<td>69.8</td>
</tr>
<tr>
<td>SGLT2 inhibitors</td>
<td>55</td>
<td>51.9</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>27</td>
<td>25.5</td>
</tr>
<tr>
<td>Pioglitazone</td>
<td>7</td>
<td>6.6</td>
</tr>
<tr>
<td>Meglitazides</td>
<td>1</td>
<td>0.9</td>
</tr>
<tr>
<td>DPP4 inhibitors</td>
<td>6</td>
<td>5.7</td>
</tr>
<tr>
<td>Insulin</td>
<td>74</td>
<td>69.8</td>
</tr>
<tr>
<td>Anti-obesity medications</td>
<td>1</td>
<td>0.9</td>
</tr>
</tbody>
</table>

98 (92.5%) patients were on subcutaneous semaglutide while the remaining 8 were on the oral drug. Eight (7.5%) patients experienced gastrointestinal side effects (mainly nausea and bloating) after initiation of semaglutide but could tolerate the drug later (4 patients had to stop the drug within 3 months of initiation of semaglutide and have not been included in the analysis).

Table 3 focuses on the baseline HbA1c and its changes over various time intervals after initiating semaglutide. Baseline mean HbA1c was 81.96 (SD 20.96) mmol/mol which reduced to 66.91 (SD 19.88) mmol/mol after one year. Figure 1 displays the HbA1c reduction trend.

Table 4 shows the paired t-test for HbA1c, and compares HbA1c at baseline to 6 months, 1 year and at the latest follow-up separately. P value was < 0.05 in each of the scenarios.

Table 5 displays the baseline body weight and its changes over time after initiating semaglutide.

Although the mean weight reduction from baseline to follow-up at 6 months and 12 months did not show statistical significance, weight loss at the latest follow-up period showed a tendency to reach significance (P = 0.057). The mean weight reduction was 12.3% from baseline. The weight loss tendency plateaued between 6-12 months. The mean decline in weight during the first 6 months was more profound than the decline which happened after 1 year to the latest follow-up. The weight reduction trend is shown in Figure 2.

Table 6 displays daily insulin requirements in the patients before and after starting semaglutide. We noted that the baseline insulin dose was lower in the females compared to males. Additionally, the dose reductions in units were greater among females compared to males. Four patients could completely stop insulin after treatment with semaglutide. The total insulin dose reduction from baseline to last follow-up was statistically significant (P = 0.024) (Figure 3).
### Table 3 Patients’ glycated hemoglobin before and after treatment with semaglutide

<table>
<thead>
<tr>
<th>Attributes</th>
<th>Male</th>
<th>Female</th>
<th>All</th>
<th>Reference value (if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td></td>
</tr>
<tr>
<td>Patient baseline HbA1c (mmol/mol)</td>
<td>84.18 (22.20)</td>
<td>79.46 (19.40)</td>
<td>81.96 (20.96)</td>
<td>20-41 mmol/mol</td>
</tr>
<tr>
<td>HbA1c after 6 months (mmol/mol)</td>
<td>68.52 (21.06)</td>
<td>67.02 (15.66)</td>
<td>67.79 (18.53)</td>
<td>20-41 mmol/mol</td>
</tr>
<tr>
<td>HbA1c after 1 yr (mmol/mol)</td>
<td>71.42 (21.94)</td>
<td>63.27 (17.48)</td>
<td>66.91 (19.88)</td>
<td>20-41 mmol/mol</td>
</tr>
<tr>
<td>Latest HbA1c (mmol/mol)</td>
<td>72.98 (25.60)</td>
<td>68.2 (19.80)</td>
<td>70.73 (23.04)</td>
<td>20-41 mmol/mol</td>
</tr>
</tbody>
</table>

HbA1c: Glycated hemoglobin.

### Table 4 Effect of semaglutide on glycemic control (glycated hemoglobin)

<table>
<thead>
<tr>
<th>HbA1c</th>
<th>Mean (SD)</th>
<th>df</th>
<th>Sig. (2-tailed) P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c baseline to 6 month</td>
<td>12.31 (17.926)</td>
<td>47</td>
<td>0.000</td>
</tr>
<tr>
<td>HbA1c baseline to 1 yr</td>
<td>14.456 (19.428)</td>
<td>47</td>
<td>0.000</td>
</tr>
<tr>
<td>HbA1c baseline to latest</td>
<td>9.644 (20.174)</td>
<td>47</td>
<td>0.002</td>
</tr>
</tbody>
</table>

HbA1c: Glycated hemoglobin.

### Table 5 Patient body weight before and after treatment with semaglutide

<table>
<thead>
<tr>
<th>Attributes</th>
<th>Male</th>
<th>Female</th>
<th>All</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Reference value (if applicable)</td>
</tr>
<tr>
<td>Patient baseline weight (kg)</td>
<td>111.45 (21.07)</td>
<td>109.05 (28.63)</td>
<td>110.36 (24.56)</td>
<td></td>
</tr>
<tr>
<td>Weight after 6 months (kg)</td>
<td>100.19 (20.98)</td>
<td>100.39 (38.57)</td>
<td>100.27 (29.13)</td>
<td></td>
</tr>
<tr>
<td>Weight after 1 year (kg)</td>
<td>102.10 (25.96)</td>
<td>98.07 (25.35)</td>
<td>99.86 (24.94)</td>
<td></td>
</tr>
<tr>
<td>Latest weight (kg)</td>
<td>101.74 (18.21)</td>
<td>90.21 (22.93)</td>
<td>96.82 (22.88)</td>
<td></td>
</tr>
</tbody>
</table>

### Table 6 Daily insulin requirement before and after treatment with semaglutide

<table>
<thead>
<tr>
<th>Attributes</th>
<th>Male</th>
<th>Female</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Daily insulin dose baseline (units)</td>
<td>106.00 (83.59)</td>
<td>81.89 (58.48)</td>
<td>95.02 (74.02)</td>
</tr>
<tr>
<td>Daily insulin dose latest (units)</td>
<td>92.2 (62.86)</td>
<td>62.14 (46.21)</td>
<td>76.45 (56.17)</td>
</tr>
</tbody>
</table>

### DISCUSSION

Several previous studies including multiple RCTs, and observational studies illustrate consistent beneficial effects of semaglutide therapy particularly in patients with diabesity. Our data revealed significant improvements in diabesity outcomes such as a mean weight reduction of 12.3% and a mean HbA1c reduction of 13.7% from baseline at the latest follow up period at a mean follow up duration of 2.6 ± 1.1 years. A mean 19.5% reduction of total insulin dose was possible in those patients who were already established on insulin management for longstanding inadequately controlled T2DM, and 4 patients could even completely stop insulin. This real-world data reinforces our understanding on the therapeutic benefits of this new GLP-1RA molecule, semaglutide, for optimal management of diabesity in day-to-day medical practice. Unfortunately, we couldn’t procure enough data in this audit sufficiently powered to analyze the cardiovascular and metabolic implications of semaglutide treatment as observed in major RCTs. However, we observed remarkably great improvements in diabesity outcomes such as HbA1c reduction and weight loss compared to those observed in large RCTs.

A recent systematic review of major clinical trials showed a mean HbA1c reduction of 0.97% (95%CI: -1.33 to -0.62) and 1.36% (95%CI: -1.59 to -1.13) with 0.5 mg and 1.0 mg of semaglutide respectively as subcutaneous (S/c) weekly injections
compared to placebo for treatment of patients with T2DM[5]. This study also very clearly showed better efficacy of this GLP-RA molecule compared to other antidiabetic medications for glycemic control with HbA1c reductions of 0.56% and 0.63% respectively when treated with 0.5 mg and 1.0 mg weekly of S/c semaglutide respectively. Our patients achieved greater mean HbA1c reduction (15.05 mmol/mol – equivalent to approximately 1.4%) at one year of follow up compared to the above meta-analysis-based study results for management of T2DM as all our patients were already on other antidiabetic medications. We acknowledge that our patients had higher baseline HbA1c (81.96 ± 20.96 mmol/mol) which could be the reason for better HbA1c reduction compared to the data revealed by clinical trials in which the baseline HbA1c was found to be comparatively lower (median HbA1c: 8.1–8.5%; 64.8–69.6 mmol/mol)[6]. Higher baseline HbA1c is known to be associated with better HbA1c reduction when treated with any antidiabetic agent including GLP-1RA as demonstrated by previous studies[7,8], which likely further explain our results with considerable HbA1c reduction. Moreover, other antidiabetic agents used by our patients (such as metformin and SGLT-2 inhibitors) would have resulted in better glycemic control. This is comparable to the observations from the SUSTAIN 9 trial, which showed that adding injectable semaglutide to patients treated for at least 90 days with SGLT-2i resulted in a significant reduction in HbA1c of an average of 1.42% (~15.55 mmol/mol)[9].

We observed a gradual worsening of metabolic control with an increase in HbA1c levels from 66.91 mmol/mol at one year to 70.73 mmol/mol in the last follow up at 2.6 ± 1.1 years. GLP-1RA medications were found to have lower efficacy in controlling chronic hyperglycemia in patients with T2DM after years of use because of various reasons such as
Figure 3 Displays the mean reduction in daily insulin requirement after initiating semaglutide.

antibody formation against some of the molecules, gradual decline in beta cell function is most patients with T2DM as part of the pathobiological behavior of the disease, and possibly a decrease in effector response to GLP-1RA drugs at the molecular level[10-13]. We believe that the slight worsening of metabolic control with a gradual increase in HbA1c level observed in our cohort at the latest follow-up could be explained by similar mechanisms.

Insulin dose reduction in a good proportion of patients was one of the interesting observations of our study which has great metabolic connotations in managing patients with diabesity. Marked improvement of glycemic control with semaglutide treatment helped insulin dose reduction in many patients and even total discontinuation of insulin in 4 patients in this cohort. Insulin dose reduction was reported by some of the RCTs and some cohort studies with the addition of semaglutide in the treatment regime[14-18]. However, we observed a mean insulin dose reduction from 95.02 to 76.45 units which is higher than the mean insulin dose reduction of 4-6 units observed by the SUSTAIN-5 Trial[15] and the study reported by Ares-Blanco et al[18] (16 units of insulin dose reduction) from Spain. Again high baseline HbA1c (82 mmol/mol) levels with a marked improvement in the metabolic control following initiation of semaglutide would explain this discrepancy, as other studies reported mean baseline HbA1c of 64 to 72 mmol/mol at the time of commencement of semaglutide treatment.

In our cohort we observed a weight reduction of 10.5 kg at 12 months’ follow up with a further improvement of body weight by another -3.04 kg at the latest follow up (a total mean weight loss of 13.54 kg) at a mean 2.6 ± 1.1 years. The reported mean weight loss observed in major RCTs with semaglutide in patients with diabesity ranged from 2.32 to 3.99 kg in an updated meta-analysis[5]. Real-world data shows variable weight loss response ranging from 4.2 kg to 9.0 kg[19, 20]. Weight loss response in patients with T2DM following semaglutide therapy could be related to various factors such as baseline body weight, ethnic-specific incretin response and the glycemia-related fluctuations in incretin physiology[13]. Higher degree of weight loss observed in our cohort could also be due to the co-administered anti-diabetic medications with synergistic weight loss potential (especially SGLT-2i) and significant insulin dose reductions.

The side effects experienced by patients in our study were mainly gastrointestinal and mild, which improved with ongoing treatment. The low rate of side effects we observed in this study compared to various other studies[5,21,22] could be related to the poor reporting of adverse events in the clinical records during follow up of the patients, a limitation unavoidable in retrospective studies.

Study limitations and implications for future research

We acknowledge a few limitations to our work which are inherent to retrospective cohort studies. Because of inadequate data, we had to exclude several cases from the analysis. Although several patients had at least annual follow-up prior to the last follow up we documented in our study, we were unable to get adequate data for analysis of these periodic follow-ups in obtaining meaningful statistical outcomes in this study. We were also unable to procure adequate data on cardiometabolic parameters such as improvement of blood pressure, lipid profile and renal outcomes because of inadequate documentation of these data in the follow-up period. Extrapolating the marked weight reduction of 12.3% into cardiometabolic outcomes from previous studies, we would have expected significant improvements in the above parameters which were not documented well in our patients’ clinical records, and this remains as a major pitfall of the study. Inadequate reporting of adverse events in the case records could have been the reason for the low incidence of side
effects observed in this study. However, the remarkable improvements in body weight, HbA1c and insulin dose reduction observed in our study bring forth the importance of appropriate use of GLP-1RA molecules including semaglutide in our day-to-day clinical practice. In fact, our data shows more profound improvements in diabesity outcomes such as marked weight loss and HbA1c reduction compared to RCT-based study data. This has important clinical implications for future research as significant weight loss in appropriately selected patients with early onset T2DM could result in diabetes remission or even reversal at least in a proportion of patients. Moreover, such patients may also have better cardiovascular benefits compared to patients with longer duration of diabetes. Therefore, compiling more real-world data with this kind of observational studies should enhance our current knowledge-base to inform better medical practice decision making in the future.

CONCLUSION

Our data shows that semaglutide use is associated with better clinical and biochemical outcomes in the real-world management of diabesity compared to the RCTs and other observational studies, with higher mean weight reduction of 12.3%, improvement of mean HbA1c by 14.5 mmol/mol (at one year), and mean insulin dose reduction of 18.6 units. Although we could not get adequate data on cardiometabolic outcomes, extrapolating the benefits of > 10% weight loss in clinical settings would have improved several of these outcomes. More data from real-world observational studies is expected to improve our understanding in using semaglutide and other newer GLP-1RA molecules for judicious management of diabesity to address the alarming rise in this clinical problem across the globe secondary to the obesity pandemic. Future research should evaluate the feasibility of early initiation of GLP-1RA such as semaglutide in patients with diabesity to see if that improves clinical and therapeutic outcomes.

ARTICLE HIGHLIGHTS

Research background
Diabesity, diabetes as a consequence of obesity, is a huge healthcare challenge across the globe and judicious use of antidiabetic medications like semaglutide is important for the optimal management as shown in randomized controlled trials (RCTs).

Research motivation
Real-world data on management of diabesity with semaglutide are also crucial for appropriate clinical practice decision making.

Research objectives
We aimed to study the real-world benefits and side effect profile of using semaglutide to manage patients with diabesity.

Research methods
In a retrospective study, we evaluated the efficacy and safety of semaglutide for managing patients with diabesity between January 2019 to May 2023 in a large academic hospital in the United Kingdom. With the relevant demographic information, we captured patients’ data from the electronic case records on improvement of glycated hemoglobin (HbA1c), body weight reduction, and insulin dose adjustments at 6 and 12 months, as well as at the latest follow up period.

Research results
Among 106 patients (56 males) with T2DM with a mean age and diabetes duration 60.8 ± 11.2 years, 12.4 ± 7.2 years respectively treated with semaglutide for a mean 2.6 ± 1.1 years, significant improvements in diabesity outcomes such as a mean weight reduction of 12.3% and HbA1c reduction of 13.7% from baseline at the latest follow-up period were observed. A mean insulin dose reduction of 19.5% from baseline was also observed at the latest follow-up as an additional benefit of semaglutide treatment. Mild gastrointestinal side effects like bloating and nausea, improving with prolonged use of semaglutide were also observed in this study.

Research conclusions
As RCTs are performed in strictly controlled research environments, the results may not always reflect patient outcomes of real-world clinical practice settings. Reviews of large-scale cohort data from real-world settings as in our study would inform better clinical practice decision making to improve the care of patients with diabesity.

Research perspectives
Significant improvements in diabesity outcomes such as reductions in body weight, HbA1c, and insulin doses were observed with semaglutide treatment, without major adverse effects in a real-world clinical practice setting.
ACKNOWLEDGEMENTS

We thank Dr. Marina George Kudiyirickal for providing us the audio for the core tip.

FOOTNOTES

Author contributions: Alkhalifah M, Afzar H and Shyams A collected the clinical data. Alkhalifah M, Shyams A and Blaibel D performed literature search, and interpretation of relevant data following statistical analysis; Alkhalifah M, Blaibel D, and Chandrabalan V contributed to the work with additional literature review and revision of the article critically for important intellectual content; Chandrabalan V also procured the patient data from the hospital electronic records; Pappachan JM contributed to the conceptual design of the paper and critically supervised the whole drafting, literature review, revision and modifications of the paper including figure construction and is the final author; All authors have read and approved the final version of the manuscript.

Institutional review board statement: The study-related audit was approved by the Institutional Audit Department.

Informed consent statement: This study is only a retrospective cohort study based on electronic case note review and therefore, patient consent is not necessary as per the standard publishing guidelines.

Conflict-of-interest statement: Authors have no conflicts of interests to declare.

Data sharing statement: Authors are happy to share the data on request.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: United Kingdom

ORCID number: Joseph M Pappachan 0000-0003-0886-5255.

S-Editor: Liu JH
L-Editor: A
P-Editor: Zhao S

REFERENCES


